血管靶向药物联合PD-1/PD-L1抗体在消化系统肿瘤治疗中的研究进展

doi:10.3760/cma.j.issn.1673-422X.2019.12.009

摘要/Abstract

摘要： 近年来，肿瘤血管靶向药物以及免疫治疗中程序性死亡蛋白-1/程序性死亡蛋白配体-1抑制剂在肿瘤治疗中均取得了很大的进步，但单一疗法不仅疗效有限，也存在耐药情况。而国内外多项临床试验结果表明，两者联合运用在消化系统肿瘤如食管癌、胃癌及胃食管连接处癌、肝癌、胰腺癌、结直肠癌治疗中具有不错的有效性及安全性，因此两者联合可能成为肿瘤治疗的一种突破性方案。

关键词: 分子靶向治疗, 血管生成抑制剂, 消化系统肿瘤, PD-1, PD-L1

Abstract: In recent years, tumor vascular targeting drugs and programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors have made great progress in tumor therapy. However, monotherapy not only has limited efficacy, but also has drug resistance. The results of many clinical trials at home and abroad showed that the combination of the two were used in the treatment of different tumors of digestive system, such as esophageal cancer, gastric cancer and gastroesophageal junction cancer, liver cancer and so on, so the combination of vascular targeting drugs and PD-1/PD-L1 antibody may be a breakthrough program in tumor therapy because of their good efficacy and safety.

Key words: Molecular targeted therapy, Angiogenesis inhibitors, Digestive system neoplasms, PD-1, PD-L1

齐瑞丽, 王华庆. 血管靶向药物联合PD-1/PD-L1抗体在消化系统肿瘤治疗中的研究进展[J]. 国际肿瘤学杂志, 2019, 46(12): 750-754.

Qi Ruili, Wang Huaqing. Research progress of tumor vascular targeting drugs combined with PD-1/PD-L1 antibody in the treatment of digestive system tumors[J]. Journal of International Oncology, 2019, 46(12): 750-754.

参考文献［34］

［1］	杜君, 郑荣寿, 庄建辉, 等. 我国食管癌疾病负担与国家自然科学基金基础研究资助情况的相关性分析［J］. 中国肿瘤, 2019, 28(4): 246-251. DOI: 10.11735/j.issn.1004-0242.2019.04.A002.
［2］	Ajani JA, Gerdes H, Bentrem DJ, et al. Esophageal and Esophagogastric Junction Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology［EB/OL］. ［2019-05-29］. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf.
［3］	A phase Ⅰ/Ⅱ study of regorafenib plus avelumab in solid tumors (REGOMUNE)［EB/OL］. ［2019-07-16］. https://www.clinicaltrials.gov/ct2/show/NCT03475953?term=NCT03475953&rank=1.
［4］	SHR-1210 in combination with apatinib and chemotherapy in patients with advanced esophageal squamous cell cancer［EB/OL］. ［2019-07-16］. https://www.clinicaltrials.gov/ct2/show/NCT03603756?term=NCT03603756&rank=1.
［5］	Combination of chemotherapy plus RT and SHR-1210 to treat patients with ESCC［EB/OL］. ［2019-07-16］. https://www.clinicaltrials.gov/ct2/show/NCT03671265?term=NCT03671265&rank=1.
［6］	孙可欣, 郑荣寿, 张思维, 等. 2015年中国分地区恶性肿瘤发病和死亡分析［J］. 中国肿瘤, 2019, 28(1): 1-11. DOI: 10.11735/j.issn.1004-0242.2019.01.A001.
［7］	Ajani JA, Farjah F, Bentrem DJ, et al. Gastric Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology［EB/OL］. ［2019-06-03］. https://www.nccn.org/professionals/physician_gls/pdf/Gastric.pdf.
［8］	Bang YJ, Golan T, Lin CC, et al. (2018) Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus durvalumab (D)［J］. J Clin Oncol, 2018, 36(4): 92. DOI: 10.1200/JCO.2018.36.4_suppl.92.
［9］	Shah MA, Metges JP, Chun PY, et al. A phase Ⅱ, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma［J］. J Clin Oncol, 2017, 35(15): TPS4141. DOI: 10.1200/JCO.2017.35.15_suppl.TPS4141.
［10］	A phase 1/2 study of ramucirumab plus nivolumab in participants with gastric or GEJ cancer［EB/OL］. ［2019-07-16］. https://www.clinicaltrials.gov/ct2/show/NCT02999295?term=NCT02999295&rank=1.
［11］	A phase Ⅱ a study of lenvatinib, a multi-targeted tyrosine kinase inhibitor, combined with pembrolizumab (PD-1 inhibitor) for the treatment of metastatic gastroesophageal cancer patients who have progressed on first or subsequent line therapies［EB/OL］. ［2019-07-16］. https://www.clinicaltrials.gov/ct2/show/NCT03321630?term=NCT03321630&rank=1.
［12］	徐琦, 应杰儿. 晚期原发性肝癌内科治疗进展［J］. 中国肿瘤, 2019, 28(5): 373-380. DOI: 10.11735/j.issn.1004-0242.2019.05.A010.
［13］	Ikeda M, Sung MW, Kudo M, et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)［J］. J Clin Oncol, 2018, 36(15_suppl): 4076. DOI: 10.1200/JCO.2018.36.15_suppl.4076.
［14］	Pishvaian MJ, Lee MS, Ryoo BY. Updated safety and clinical activity results from a phase Ⅰb study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)［J］. Ann Oncol, 2018, 29 (8): LBA26. DOI: 10.1093/annonc/mdy424.028.
［15］	A study of atezolizumab in combination with bevacizumab compared with sorafenib in patients with untreated locally advanced or metastatic hepatocellular carcinoma ［IMbrave150］ (IMbrave150)［EB/OL］. ［2019-07-16］. https://www.clinicaltrials.gov/ct2/show/NCT03434379?term=NCT03434379&rank=1.
［16］	Sorafenib tosylate and pembrolizumab in treating patients with advanced or metastatic liver cancer［EB/OL］. ［2019-07-16］. https://www.clinicaltrials.gov/ct2/show/NCT03211416?term=NCT03211416&rank=1.
［17］	Safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus lenvatinib as first-line therapy in participants with advanced hepatocellular carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)［EB/OL］. ［2019-07-16］. https://www.clinicaltrials.gov/ct2/show/NCT03713593?term=NCT03713593&rank=1.
［18］	Seufferlein T, Mayerle J. Pancreatic cancer in 2015: precision medicine in pancreatic cancer-fact or fiction?［J］. Nat Rev Gastroenterol Hepatol, 2016, 13(2): 74-75. DOI: 10.1038/nrgastro.2015.215.
［19］	Adamska A, Domenichini A, Falasca M. Pancreatic ductal adenocarcinoma: current and evolving therapies［J］. Int J Mol Sci, 2017, 18(7). pii: E1338. DOI: 10.3390/ijms18071338.
［20］	Ioka T, Okusaka T, Ohkawa S, et al. Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized phase Ⅲ trial［J］. Jpn J Clin Oncol, 2015, 45(5): 439-448. DOI: 10.1093/jjco/hyv011.
［21］	Middleton G, Palmer DH, Greenhalf W, et al. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial［J］. Lancet Oncol, 2017, 18(4): 486-499. DOI: 10.1016/S1470-2045(17)30084-0.
［22］	Sun D, Ma J, Wang J, et al. Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort［J］. Ther Clin Risk Manag, 2018, 14: 1691-1700. DOI: 10.2147/TCRM.S173041.
［23］	Cappello P, Curcio C, Mandili G, et al. Next generation immunotherapy for pancreatic cancer: DNA vaccination is seeking new combo partners［J］. Cancers (Basel), 2018, 10(2). pii: E51. DOI: 10.3390/cancers10020051.
［24］	Jiang H, Hegde S, Knolhoff BL, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy［J］. Nat Med, 2016, 22(8): 851-860. DOI: 10.1038/nm.4123.
［25］	Atezolizumab and bevacizumab in treating patients with rare solid tumors［EB/OL］. ［2019-07-16］. https://www.clinicaltrials.gov/ct2/show/NCT03074513?term=NCT03074513&rank=1.
［26］	QUILT3.039: NANT pancreatic cancer vaccine: combination immunotherapy in subjects with pancreatic cancer who have progressed on or after standard-of-care therapy［EB/OL］. ［2019-07-16］. https://www.clinicaltrials.gov/ct2/show/NCT03136406?term=NCT03136406&rank=1.
［27］	QUILT-3.088: NANT pancreatic cancer vaccine［EB/OL］. ［2019-07-16］. https://www.clinicaltrials.gov/ct2/show/NCT03563144?term=NCT03563144&rank=1.
［28］	Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade［J］. Science, 2017, 357(6349): 409-413. DOI: 10.1126/science.aan6733.
［29］	Overman MJ, Mcdermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repairdeficient or microsatellite instability-high colorectal cancer (CheckMate142): an open-label, multicentre, phase 2 study［J］. Lancet Oncol, 2017, 18(9): 1182-1191. DOI: 10.1016/S1470-2045(17)30422-9.
［30］	Wallin J, Pishvaian MJ, Hernandez G, et al. Clinical activity and immune correlates from a phase Ⅰb study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma［J］. Cancer Research, 2016, 76(14): 2651. DOI: 10.1158/1538-7445.AM2016-2651.
［31］	Hochster HS, Bendell JC, Cleary JM, et al. Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ⅰb study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC)［J］. J Clin Oncol, 2017, 35(4_suppl): 673. DOI: 10.1200/JCO.2017.35.4_suppl.673.
［32］	Grothey A, Tabernero J, Arnold D, et al. Fluoropyrimidine (FP)+ bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): findings from cohort 2 of MODUL-a multicentre, randomized trial of biomarkerdriven maintenance treatment following first-line induction therapy［J］. Ann Oncol, 2018, 29(8): LBA19. DOI: 10.1093/annonc/mdw424.020.
［33］	Capecitabine and bevacizumab with or without atezolizumab in treating patients with refractory metastatic colorectal cancer［EB/OL］. ［2019-07-16］. https://www.clinicaltrials.gov/ct2/show/NCT02873195?term=NCT02873195&rank=1.
［34］	Combination chemotherapy, bevacizumab, and/or atezolizumab in treating patients with deficient dna mismatch repair metastatic colorectal cancer［EB/OL］. ［2019-07-16］. https://www.clinicaltrials.gov/ct2/show/NCT02997228?term=NCT02997228& rank=1.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[5]	马正红, 姜超. 非小细胞肺癌KRAS^G12C突变的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 95-98.
[6]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[7]	李开春, 丁昌利, 于文艳. 安罗替尼联合特瑞普利单抗治疗晚期肺肉瘤样癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 511-512.
[8]	陈秋, 王雷, 王明琦, 张梅. 恩沃利单抗联合阿昔替尼治疗肾癌肺转移1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 445-448.
[9]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[10]	刘利, 朱思齐, 孙梦颖, 何敬东. PARP抑制剂在小细胞肺癌靶向治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(6): 368-372.
[11]	刘博翰, 黄俊星. 溶质载体SLC7A5及SLC7A11基因在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 280-284.
[12]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[13]	邓莉莉, 段星宇, 李保中. HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757.
[14]	刘绍平, 罗汉传, 林书瀚, 罗家辉. 中晚期肝细胞癌介入及系统治疗的现状与研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 758-762.
[15]	江山, 徐细明. 肝细胞癌的靶向及免疫治疗新进展[J]. 国际肿瘤学杂志, 2023, 50(11): 688-695.